STOCK TITAN

Avenue Therapeutics, Inc. - ATXI STOCK NEWS

Welcome to our dedicated page for Avenue Therapeutics news (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.

Avenue Therapeutics, Inc. (NASDAQ: ATXI), a subsidiary of Fortress Biotech (NASDAQ: FBIO), is a specialty pharmaceutical company headquartered in Miami, FL. Avenue focuses on developing and commercializing therapies for the treatment of neurologic diseases. The company's core product pipeline includes AJ201 for spinal and bulbar muscular atrophy (SBMA), BAER-101 for epilepsy and panic disorders, and IV tramadol for moderate-to-moderately-severe postoperative pain management. Avenue is currently engaged in a pivotal Phase 3 program for IV tramadol, which aims to fill a therapeutic gap in the acute pain market between IV acetaminophen/NSAIDs and conventional narcotics. AJ201, designed for SBMA or Kennedy’s Disease, is in the Phase 1b/2a clinical trial stage, with topline data expected in mid-2024. Additionally, BAER-101 has shown promising preclinical results in epilepsy models and is slated for further development contingent on financing. The company continues to advance its innovative drug pipeline while maintaining strategic partnerships and exploring new opportunities for growth in the pharmaceutical market. Recent achievements include completion of patient enrollment for AJ201’s Phase 1b/2a trial, FDA alignment on the Phase 3 safety study for IV tramadol, and multiple public equity offerings raising substantial gross proceeds. Avenue's commitment to providing impactful therapies to patients with unmet medical needs underscores its significance in the specialty pharmaceutical sector. For more information, visit www.avenuetx.com.

Rhea-AI Summary
Avenue Therapeutics, Inc. has closed its public offering, raising approximately $5.0 million. The offering consisted of 16,633,400 units at a price of $0.3006 per unit. Each unit included one share of common stock, one Series A warrant, and one Series B warrant. Maxim Group LLC and Lake Street Capital Markets, LLC acted as placement agents for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
-
Rhea-AI Summary
Avenue Therapeutics, Inc. has announced the pricing of its public offering of 16,633,400 units at a price of $0.3006 per unit. Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant. The gross proceeds from the offering are expected to be approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.05%
Tags
-
Rhea-AI Summary
Avenue Therapeutics CEO to present corporate update at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
conferences
Rhea-AI Summary
Avenue Therapeutics reports progress in clinical trials and agreement with FDA on study design for IV tramadol. First patient dosed in Phase 1b/2a trial of AJ201 for SBMA. Positive preclinical data for BAER-101 in epilepsy. Financial results show decrease in cash and increase in expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary
Avenue Therapeutics announces positive preclinical results for BAER-101 in epilepsy treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
-
Rhea-AI Summary
Avenue Therapeutics announces the dosing of the first patient in the Phase 1b/2a clinical trial of AJ201 for the treatment of SBMA. The trial is expected to be completed by the end of 2023 or early 2024, with potential topline data in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
Rhea-AI Summary
Avenue Therapeutics has reached an agreement with the FDA on key elements of the Phase 3 safety study for its intravenous tramadol, which is being developed for the treatment of acute post-operative pain. The study will assess the risk of opioid-induced respiratory depression compared to IV morphine. The company believes that IV tramadol will prove to be safe and effective based on its mechanism of action and positive data from previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
-
Rhea-AI Summary

Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focused on neurologic diseases, will present a corporate update at the Aegis Capital Virtual Conference on May 4, 2023, at 4:00 p.m. EDT. CEO Alexandra MacLean will lead the presentation. Interested participants can access the zoom link on Avenue's website for 30 days post-event. Avenue is developing three key assets: AJ201 for spinal and bulbar muscular atrophy, BAER-101 for CNS diseases, and IV Tramadol, currently in Phase 3 clinical development for pain management. Founded by Fortress Biotech, Avenue Therapeutics is headquartered in Miami, FL.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
Rhea-AI Summary

Avenue Therapeutics, Inc. (Nasdaq: ATXI) has received official meeting minutes from the FDA following a Type C meeting on March 9, 2023, regarding the development of IV Tramadol for post-operative pain management. The FDA agreed on most aspects of the proposed study protocol, addressing the risk of opioid-induced respiratory depression compared to IV morphine. This follows earlier discussions in August 2022, where the FDA found the proposed study design reasonable. Avenue aims to finalize the protocol based on FDA feedback, with plans to initiate a Phase 3 safety study in 2023. A successful trial outcome could pave the way for IV Tramadol's approval. Avenue also plans to update on its additional programs targeting spinal muscular atrophy and epilepsy later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.09%
Tags
none

FAQ

What is the current stock price of Avenue Therapeutics (ATXI)?

The current stock price of Avenue Therapeutics (ATXI) is $2.01 as of November 22, 2024.

What is the market cap of Avenue Therapeutics (ATXI)?

The market cap of Avenue Therapeutics (ATXI) is approximately 3.8M.

What is Avenue Therapeutics, Inc.'s primary focus?

Avenue Therapeutics, Inc. focuses on developing and commercializing therapies for the treatment of neurologic diseases, including SBMA, epilepsy, and acute postoperative pain.

What are the main products in Avenue Therapeutics' pipeline?

The main products are AJ201 for spinal and bulbar muscular atrophy (SBMA), BAER-101 for epilepsy and panic disorders, and IV tramadol for moderate-to-moderately-severe postoperative pain.

What is the current status of AJ201?

AJ201 is in Phase 1b/2a clinical trials for the treatment of spinal and bulbar muscular atrophy. Topline data from this trial are expected in mid-2024.

What recent achievements has Avenue Therapeutics made?

Recent achievements include completing patient enrollment for AJ201’s Phase 1b/2a trial, reaching FDA agreement on the Phase 3 safety study for IV tramadol, and raising substantial funds through public equity offerings.

How does IV tramadol fit into the acute pain market?

IV tramadol aims to fill a gap in the acute pain market by providing a pain management option that falls between IV acetaminophen/NSAIDs and conventional narcotics.

What are the future plans for BAER-101?

BAER-101, which has shown promising preclinical results, is planned to enter Phase 2a clinical trials to further study its anti-seizure properties in patients with epilepsy, pending additional financing.

Who founded Avenue Therapeutics, Inc.?

Avenue Therapeutics, Inc. was founded by Fortress Biotech, Inc. (NASDAQ: FBIO).

Where is Avenue Therapeutics headquartered?

Avenue Therapeutics is headquartered in Miami, FL.

How does Avenue Therapeutics aim to enhance shareholder value?

Avenue Therapeutics aims to enhance shareholder value by advancing its clinical pipeline, securing regulatory approvals, and providing impactful therapies to patients with neurologic diseases.

Where can I find more information about Avenue Therapeutics' clinical trials?

More detailed information about Avenue Therapeutics’ clinical trials can be found on their official website at www.avenuetx.com.

Avenue Therapeutics, Inc.

Nasdaq:ATXI

ATXI Rankings

ATXI Stock Data

3.84M
1.48M
9.85%
10.33%
3.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BAY HARBOR ISLANDS